Aspirin Fails Noninferiority Test for VTE Prevention After Joint Replacement
Large comparative trial shows anticoagulants outperform aspirin in preventing venous thromboembolism following arthroplasty surgery.
1Trial Results Overview
The PEPPER trial investigated venous thromboembolism prevention following elective hip or knee replacements. Researchers found that aspirin failed to demonstrate noninferiority compared to warfarin or rivaroxaban. The primary composite endpoint included death or symptomatic VTE over six months, revealing higher event rates in the aspirin group compared to the anticoagulant cohorts.
2Primary Effectiveness Data
Event rates for the primary effectiveness outcome were 1.26% for aspirin, 1.23% for warfarin, and 0.94% for rivaroxaban. Statistical analysis confirmed that aspirin did not meet the required noninferiority criteria against either anticoagulant. Conversely, the comparison between warfarin and rivaroxaban successfully met the noninferiority threshold, highlighting a clear performance gap for aspirin.
3Safety Profile Comparison
Safety outcomes, including bleeding, wound complications, and myocardial infarction, were also tracked across the three groups. Risks were 3.65% for warfarin versus 2.88% for aspirin, and 3.70% for rivaroxaban versus 3.02% for aspirin. None of these safety comparisons met the noninferiority criteria, suggesting that anticoagulants carry a higher risk of adverse events.
4Clinical Practice Context
Orthopedic surgeons in North America frequently favor aspirin due to its low cost, minimal bleeding risk, and lack of required monitoring. Despite this preference, evidence supporting its efficacy compared to anticoagulants remained limited until now. This trial provides critical data to inform preoperative decision-making for patients undergoing elective joint replacement procedures.
5Methodological Challenges
The study involved 15,317 patients across 34 centers in the U.S. and Canada. However, the trial faced significant limitations due to high crossover rates, where patients switched from assigned anticoagulants to aspirin. This movement, driven by cost and monitoring burdens, potentially introduced unmeasured confounding that compromised the original randomization benefits.
6Contrasting Research Findings
These results appear to conflict with the earlier EPCAT III trial, which suggested aspirin was as effective as rivaroxaban. Experts argue these studies tell parallel stories, indicating that a short course of anticoagulation followed by aspirin might be the optimal strategy for average-risk patients undergoing hip or knee arthroplasty surgery.
7Patient Cohort Disparities
The per-protocol aspirin cohort was significantly larger than the anticoagulant groups despite similar initial randomization numbers. Specifically, the aspirin group was 22% larger than the rivaroxaban cohort and 44% larger than the warfarin cohort. These imbalances reflect the pragmatic nature of the comparative-effectiveness design and the challenges of maintaining long-term adherence.
8Future Clinical Implications
The findings underscore the complexity of balancing VTE prevention with bleeding risks in orthopedic surgery. Clinicians should consider these comparative risk-benefit profiles when selecting prophylaxis. Future protocols may increasingly adopt hybrid approaches, combining short-term anticoagulant use with subsequent aspirin therapy to maximize patient safety while maintaining effective protection against thromboembolic events.